<DOC>
	<DOCNO>NCT00004840</DOCNO>
	<brief_summary>OBJECTIVES : I. Assess efficacy safety antenatal administration thyrotropin-releasing hormone woman premature labor improve pulmonary outcome preterm infant .</brief_summary>
	<brief_title>Study Antenatal Thyrotropin-Releasing Hormone Women Premature Labor Prevent Lung Disease Preterm Infants</brief_title>
	<detailed_description>PROTOCOL OUTLINE : This randomize , double blind , multicenter study . Patients randomize receive antenatal thyrotropin-releasing hormone placebo . Patients receive thyrotropin-releasing hormone placebo intravenously 20 minute every 8 hour 4 dos . Infants assess survival chronic lung disease day 28 birth , 36 postmenstrual week .</detailed_description>
	<mesh_term>Respiratory Distress Syndrome , Newborn</mesh_term>
	<mesh_term>Respiratory Distress Syndrome , Adult</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Thyrotropin-Releasing Hormone</mesh_term>
	<mesh_term>Calcitonin</mesh_term>
	<criteria>Pregnant woman active labor 2429 week gestation Not eligible follow present : Bleeding Infection Hypertension ( great 140/90 mmHg ) Fetus hydrops lifethreatening anomaly One dead fetus multiple pregnancy</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>36 Years</maximum_age>
	<verification_date>October 1998</verification_date>
	<keyword>cardiovascular respiratory disease</keyword>
	<keyword>neonatal disorder</keyword>
	<keyword>rare disease</keyword>
	<keyword>respiratory distress syndrome</keyword>
</DOC>